Difference between revisions of "Template:Antithrombotics"
Jump to navigation
Jump to search
blackwiki>Jeetmahal (betrixaban is in Phase 3 trials currently) |
m (131 revisions imported) |
||
| (11 intermediate revisions by 8 users not shown) | |||
| Line 12: | Line 12: | ||
* [[Abciximab]] | * [[Abciximab]] | ||
* [[Eptifibatide]] | * [[Eptifibatide]] | ||
| + | * [[Orbofiban]] | ||
| + | * [[Roxifiban]] | ||
| + | * [[Sibrafiban]]<sup>§</sup> | ||
* [[Tirofiban]] | * [[Tirofiban]] | ||
| − | |||
| − | |||
| group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] | | group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] | ||
| Line 45: | Line 46: | ||
| list5 = | | list5 = | ||
* [[Thromboxane synthase inhibitors]] | * [[Thromboxane synthase inhibitors]] | ||
| − | ** [[Dipyridamole]] ([[Acetylsalicylic acid/dipyridamole|+ | + | ** [[Dipyridamole]] ([[Acetylsalicylic acid/dipyridamole|+ aspirin]]) |
** [[Picotamide]] | ** [[Picotamide]] | ||
| + | ** [[Terbogrel]] | ||
* [[Thromboxane receptor antagonist|Receptor antagonist]]s | * [[Thromboxane receptor antagonist|Receptor antagonist]]s | ||
| − | ** [[Terutroban]]<sup> | + | ** [[Terbogrel]] |
| + | ** [[Terutroban]]<sup>§</sup> | ||
| group6 = [[Phosphodiesterase inhibitor]]s | | group6 = [[Phosphodiesterase inhibitor]]s | ||
| Line 86: | Line 89: | ||
| group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) | | group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) | ||
| list1 = | | list1 = | ||
| − | * [[Low molecular weight heparin]] | + | * [[Low-molecular-weight heparin]] |
** [[Bemiparin sodium|Bemiparin]] | ** [[Bemiparin sodium|Bemiparin]] | ||
** [[Certoparin sodium|Certoparin]] | ** [[Certoparin sodium|Certoparin]] | ||
| Line 94: | Line 97: | ||
** [[Parnaparin sodium|Parnaparin]] | ** [[Parnaparin sodium|Parnaparin]] | ||
** [[Reviparin sodium|Reviparin]] | ** [[Reviparin sodium|Reviparin]] | ||
| − | ** [[Tinzaparin sodium|Tinzaparin]] | + | ** [[Tinzaparin sodium|Tinzaparin]] |
* [[Oligosaccharide]]s | * [[Oligosaccharide]]s | ||
** [[Fondaparinux]] | ** [[Fondaparinux]] | ||
| Line 103: | Line 106: | ||
** [[Sulodexide]] | ** [[Sulodexide]] | ||
| − | | group2 = [[Direct Xa inhibitor]]s | + | | group2 = [[Direct Xa inhibitor]]s ("xabans") |
| list2 = | | list2 = | ||
| − | + | * [[Apixaban]] | |
| − | + | * [[Betrixaban]] | |
| − | + | * [[Darexaban]]<sup>§</sup> | |
| − | + | * [[Edoxaban]] | |
| − | + | * [[Otamixaban]]<sup>§</sup> | |
| − | + | * [[Rivaroxaban]] | |
| − | |||
}} | }} | ||
| Line 125: | Line 127: | ||
* [[Direct thrombin inhibitor#Univalent|Univalent]]: [[Argatroban]] | * [[Direct thrombin inhibitor#Univalent|Univalent]]: [[Argatroban]] | ||
* [[Dabigatran]] | * [[Dabigatran]] | ||
| + | * [[Efegatran]] | ||
| + | * [[Inogatran]]<sup>§</sup> | ||
* [[Melagatran]]<sup>‡</sup> | * [[Melagatran]]<sup>‡</sup> | ||
* [[Ximelagatran]]<sup>‡</sup> | * [[Ximelagatran]]<sup>‡</sup> | ||
| Line 142: | Line 146: | ||
| list3 = | | list3 = | ||
* [[Plasminogen activator]]s: [[Recombinant tissue plasminogen activators|r-tPA]] | * [[Plasminogen activator]]s: [[Recombinant tissue plasminogen activators|r-tPA]] | ||
| − | ** [[ | + | ** [[Alteplase]] |
** [[Reteplase]] | ** [[Reteplase]] | ||
** [[Tenecteplase]] | ** [[Tenecteplase]] | ||
| + | ** [[Desmoteplase]]<sup>†</sup> | ||
* UPA | * UPA | ||
** [[Saruplase]] | ** [[Saruplase]] | ||
| Line 155: | Line 160: | ||
* [[Fibrinolysin]] | * [[Fibrinolysin]] | ||
| − | | group4 = [[Anticoagulant | + | | group4 = [[Anticoagulant|Non-medicinal]] |
| list4 = | | list4 = | ||
* [[Citrate]] | * [[Citrate]] | ||
| Line 162: | Line 167: | ||
| belowstyle = background: transparent; padding: 0px; | | belowstyle = background: transparent; padding: 0px; | ||
| − | | below = {{PharmNavFootnote | + | | below = {{PharmNavFootnote}} |
}}<noinclude> | }}<noinclude> | ||
Latest revision as of 14:27, 22 October 2020
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Antithrombotics|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Antithrombotics|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Antithrombotics|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.